image
Healthcare - Biotechnology - NASDAQ - US
$ 1.44
11.6 %
$ 327 M
Market Cap
-6.55
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one GOSS stock under the worst case scenario is HIDDEN Compared to the current market price of 1.44 USD, Gossamer Bio, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one GOSS stock under the base case scenario is HIDDEN Compared to the current market price of 1.44 USD, Gossamer Bio, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one GOSS stock under the best case scenario is HIDDEN Compared to the current market price of 1.44 USD, Gossamer Bio, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart GOSS

image
$1.6$1.6$1.5$1.5$1.4$1.4$1.3$1.3$1.2$1.2$1.1$1.1$1.0$1.0$0.9$0.9$0.8$0.8$0.7$0.7Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
115 M REVENUE
0.00%
-59.9 M OPERATING INCOME
67.39%
-56.5 M NET INCOME
68.56%
-3.47 M OPERATING CASH FLOW
97.82%
29 M INVESTING CASH FLOW
126.15%
-11.5 M FINANCING CASH FLOW
-6.04%
9.89 M REVENUE
5.44%
-36.8 M OPERATING INCOME
-1.89%
-36.6 M NET INCOME
-10.93%
-39.7 M OPERATING CASH FLOW
-11.96%
22.1 M INVESTING CASH FLOW
-58.54%
504 K FINANCING CASH FLOW
0.00%
Balance Sheet Gossamer Bio, Inc.
image
Current Assets 310 M
Cash & Short-Term Investments 295 M
Receivables 5.54 M
Other Current Assets 9.83 M
Non-Current Assets 5.4 M
Long-Term Investments 0
PP&E 5.12 M
Other Non-Current Assets 283 K
93.41 %3.12 %Total Assets$315.3m
Current Liabilities 45 M
Accounts Payable 2.32 M
Short-Term Debt 961 K
Other Current Liabilities 41.7 M
Non-Current Liabilities 241 M
Long-Term Debt 202 M
Other Non-Current Liabilities 38.9 M
14.60 %70.65 %13.60 %Total Liabilities$285.8m
EFFICIENCY
Earnings Waterfall Gossamer Bio, Inc.
image
Revenue 115 M
Cost Of Revenue 0
Gross Profit 115 M
Operating Expenses 175 M
Operating Income -59.9 M
Other Expenses -3.39 M
Net Income -56.5 M
120m120m100m100m80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)115m0115m(175m)(60m)3m(57m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-52.24% OPERATING MARGIN
-52.24%
-49.28% NET MARGIN
-49.28%
-191.67% ROE
-191.67%
-17.93% ROA
-17.93%
-22.45% ROIC
-22.45%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Gossamer Bio, Inc.
image
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -56.5 M
Depreciation & Amortization 4.15 M
Capital Expenditures 0
Stock-Based Compensation 20.6 M
Change in Working Capital 39.5 M
Others 29.9 M
Free Cash Flow -3.47 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Gossamer Bio, Inc.
image
Wall Street analysts predict an average 1-year price target for GOSS of $5.4 , with forecasts ranging from a low of $2 to a high of $12 .
GOSS Lowest Price Target Wall Street Target
2 USD 38.89%
GOSS Average Price Target Wall Street Target
5.4 USD 275.00%
GOSS Highest Price Target Wall Street Target
12 USD 733.33%
Price
Max Price Target
Min Price Target
Average Price Target
121210108866442200Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 16
6. Ownership
Insider Ownership Gossamer Bio, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
1.26 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
324 K USD 3
9-12 MONTHS
7. News
Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced enrollment completion for the ongoing, global registrational Phase 3 PROSERA Study evaluating seralutinib in Functional Class II and III PAH patients. Gossamer Bio and t. businesswire.com - 6 days ago
Squarepoint Ops LLC Has $65,000 Stake in Gossamer Bio, Inc. (NASDAQ:GOSS) Squarepoint Ops LLC trimmed its stake in Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report) by 51.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 71,944 shares of the company’s stock after selling 75,013 shares during the period. Squarepoint Ops LLC’s holdings in Gossamer Bio were worth $65,000 at the end of the most recent reporting period. Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GOSS. Two Sigma Investments LP grew its position in shares of Gossamer Bio by 41.3% in the fourth quarter. Two Sigma Investments LP now owns 891,279 shares of the company’s stock valued at $806,000 after purchasing an additional 260,318 shares during the last quarter. Two Sigma Advisers LP grew its holdings in Gossamer Bio by 44.7% in the 4th quarter. Two Sigma Advisers LP now owns 1,157,500 shares of the company’s stock valued at $1,047,000 after buying an additional 357,500 shares during the last quarter. Octagon Capital Advisors LP grew its holdings in Gossamer Bio by 99.7% in the 4th quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company’s stock valued at $16,599,000 after buying an additional 9,162,117 shares during the last quarter. Millennium Management LLC grew its holdings in Gossamer Bio by 14.6% in the 4th quarter. Millennium Management LLC now owns 3,586,067 shares of the company’s stock valued at $3,244,000 after buying an additional 457,179 shares during the last quarter. Finally, Lazard Asset Management LLC grew its holdings in Gossamer Bio by 7,992.6% in the 4th quarter. Lazard Asset Management LLC now owns 107,470 shares of the company’s stock valued at $97,000 after buying an additional 106,142 shares during the last quarter. 81.23% of the stock is currently owned by institutional investors and hedge funds. Gossamer Bio Price Performance Shares of GOSS stock opened at $1.25 on Wednesday. Gossamer Bio, Inc. has a 12-month low of $0.51 and a 12-month high of $1.55. The firm has a market capitalization of $284.13 million, a price-to-earnings ratio of -3.91 and a beta of 1.85. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64. The firm has a fifty day moving average of $1.03 and a 200-day moving average of $1.04. Gossamer Bio (NASDAQ:GOSS – Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.02. The business had revenue of $9.89 million for the quarter, compared to the consensus estimate of $3.95 million. On average, equities research analysts forecast that Gossamer Bio, Inc. will post -0.28 earnings per share for the current year. Wall Street Analysts Forecast Growth GOSS has been the topic of a number of recent research reports. The Goldman Sachs Group lifted their target price on Gossamer Bio from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, May 16th. Wedbush reissued an “outperform” rating and set a $4.00 target price on shares of Gossamer Bio in a research report on Friday, May 16th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Gossamer Bio in a research report on Tuesday, March 18th. Check Out Our Latest Report on GOSS About Gossamer Bio (Free Report) Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. See Also Five stocks we like better than Gossamer Bio How to Profit From Growth Investing AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway High Dividend REITs: Are They an Ideal Way to Diversify? Casey’s Surges on Strong Q4, More Gains Likely Ahead What Are Dividend Achievers? An Introduction Government Mandate Sends eVTOL Stocks Flying Want to see what other hedge funds are holding GOSS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report). https://www.defenseworld.net - 1 week ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective June 5th, 2025, to three non-executive employees of non-qualified stock op. businesswire.com - 2 weeks ago
Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript Gossamer Bio, Inc. (NASDAQ:GOSS ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Bryan Giraudo - COO & CFO Faheem Hasnain - Co-Founder, CEO, President & Chairman Richard Aranda - Chief Medical Officer Caryn Peterson - EVP, Regulatory Affairs Bob Smith - Chief Commercial Officer Conference Call Participants Joseph Schwartz - SVB Leerink Andreas Argyrides - Oppenheimer Yasmeen Rahimi - Piper Sandler & Co. Paul Choi - Goldman Sachs Olivia Brayer - Cantor Patrick Trucchio - HC Wainwright Laura Chico - Wedbush Operator Good afternoon, ladies and gentlemen, and welcome to the Gossamer Bio Q1 2025 Earnings Call. I will now turn the program over to Bryan Giraudo, Chief Financial Officer and Chief Operating Officer. seekingalpha.com - 1 month ago
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates Gossamer Bio (GOSS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.19 per share a year ago. zacks.com - 1 month ago
Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter ended March 31, 2025, and announced the closure of new patient screening for the ongoing registrational Phase 3 PROSERA Study. businesswire.com - 1 month ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective May 5, 2025, to three non-executive employees of non-qualified stock optio. businesswire.com - 1 month ago
Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present a poster at the American Thoracic Society (ATS) 2025 International Conference, taking place from May 16th through 21st, in San Francisco, Califor. businesswire.com - 1 month ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective April 7, 2025, to one non-executive employee of non-qualified stock option. businesswire.com - 2 months ago
Gossamer Bio (GOSS) Reports Q4 Loss, Tops Revenue Estimates Gossamer Bio (GOSS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago. zacks.com - 3 months ago
Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December 31, 2024, and provided a business update. “As we close the book on 2024 and embrace the promise of 2. businesswire.com - 3 months ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective March 5, 2025, to five non-executive employees of non-qualified stock opti. businesswire.com - 3 months ago
8. Profile Summary

Gossamer Bio, Inc. GOSS

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 327 M
Dividend Yield 0.00%
Description Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Contact 3013 Science Park Road, San Diego, CA, 92121 https://www.gossamerbio.com
IPO Date Feb. 8, 2019
Employees 144
Officers Mr. Jeff Boerneke General Counsel & Secretary Dr. Robert F. Roscigno Ph.D. Senior Vice President of Clinical Development of Pulmonary Vascular Disease Mr. Christian Waage J.D. Executive Vice President of Technical Operations & Administration Mr. Matt Cravets Senior Vice President of Biometrics Ms. Caryn L. Peterson Executive Vice President of Regulatory Affairs Ms. Jeanine Anthony Senior Vice President of Marketing Ms. Deanna Weber Senior Vice President of Human Resources Mr. Faheem Hasnain Co-Founder, Chief Executive Officer, President & Chairman Mr. Bryan Giraudo Chief Operating Officer & Chief Financial Officer Dr. Richard Aranda M.D. Chief Medical Officer